| Autor: |
Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Cohen, I. J., Nasta, S. D., Landsburg, D. J., Gerson, J. N., Carter, J. S., Barta, S. K., Yelton, R., Pajarillo, R., Ballard, H. J., Weber, E., Napier, E. B., Chong, E. R., Fraietta, J. A., Garfall, A. L., Porter, D. L., Schuster, S. J. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p201-201, 1p |
| Abstrakt: |
We previously demonstrated that Bendamustine (Benda) LD is as effective as standard fludarabine and cyclophosphamide (Flu/Cy) LD before the 4-1BB-costimulated tisagenlecleucel, but has reduced cytokine-release syndrome (CRS), neurotoxicity (ICANS), and hematological toxicities. B Introduction: b Lymphodepletion (LD) is a key component of anti-CD19 chimeric antigen receptor T cell (CART19) immunotherapy, establishing the proper environment and cytokine milieu before CART infusion. BENDAMUSTINE LYMPHODEPLETION TRIGGERS REDUCED INFLAMMATORY CYTOKINES AND DECREASED TOXICITIES AFTER BOTH 4-1BB- AND CD28-COSTIMULATED CART19 FOR NON-HODGKIN LYMPHOMA. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text